ClinicalTrials.gg
CompletedNCT05936151Updated Nov 9, 2026Results posted

A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

A Phase 2 interventional study of Retatrutide and Placebo in Overweight or Obesity, CKD and Type 2 Diabetes, sponsored by Eli Lilly and Company. Completed at 42 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Updated Nov 9, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
146
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 16 studies testing retatrutide in Obesity — 1 open to participants now, 6 under way, 5 of them phase 3. retatrutide · Obesity.

Enrollment
12th of 16
146 · median 392
Started
2023
with 5 others
Phase 2
3 of 16
1 open now
Registered
8th of 16
by date
Lead sponsor
15 of 16
Eli Lilly and Company

Among the 16 studies testing retatrutide in Obesity, this one is the 12th largest by enrollment, is one of 6 that started in 2023, is one of 3 in phase 2, and was the 8th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

Browse Obesity studies →

Open to participants now

1 of the 16 studies testing retatrutide in Obesity is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About retatrutide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing retatrutide in Obesity, or all of them as a file.
02

Study summary

The main purpose of this study is to investigate the effect of retatrutide on renal function in participants with overweight or obesity and chronic kidney disease (CKD), with or without Type 2 Diabetes (T2D). The study will last around 31 weeks.

03

Conditions studied

  • Overweight or Obesity
  • CKD
  • Type 2 Diabetes

Browse trials for

04

In context

Obesity Reclassified

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

This study's enrollment of 146 is above the median of 67 across 9,016 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a (BMI) ≥27 kilogram/square meter (kg/m²)
  • Have either

    • no T2D with an \< 6.5% or
    • have T2D with an HbA1c ≤ 9.5% and treated with diet and exercise only or with stable doses of up to 3 oral antihyperglycemic medications, with or without basal insulin for at least 90 days before screening.
  • Have been diagnosed with chronic kidney disease (CKD).

Exclusion criteria

Exclusion Criteria:

  • Have a self-reported change in body weight >5 kilogram (kg) (11 pounds) within 90 days before screening.
  • Have used in 90 days before the screening any of the following antihyperglycemic class: Dipeptidyl Peptidase IV (DPP4) inhibitors, amylin analogs, glucagon-like peptide-RA (GLP-RA), gastric inhibitory polypeptide (GIP)/GIP-1 RA, and short acting or rapid acting insulins or U500 Insulin
  • Have a prior or planned surgical treatment for obesity
  • Have Type 1 Diabetes (T1D)
  • Have acute or chronic hepatitis
  • Have a history of malignant disease within 5 years before screening.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
146 participants (actual)

Study arms

  • Experimental
    Retatrutide

    Participants received retatrutide administered subcutaneously once weekly for approximately 24 weeks. Treatment was initiated at 2 milligrams (mg) once weekly and escalated every 4 weeks to 4 mg, 6 mg, 9 mg, and 12 mg. The target maintenance dose was 12 mg once weekly. Participants who did not tolerate the 12 mg dose could remain on a maintenance dose of 4 mg, 6 mg, or 9 mg.

    Drug: Retatrutide

  • Placebo comparator
    Placebo

    Participants received placebo matched retatrutide administered subcutaneously once weekly for approximately 24 weeks. To maintain blinding, participants followed a sham dose-escalation schedule with changes in administered volume every 4 weeks to match the retatrutide dose-escalation schedule.

    Drug: Placebo

Interventions

  • Administered Subcutaneously

    Also known as: LY3437943

  • DrugPlacebo

    Administered Subcutaneously

07

What researchers measure

Primary outcomes

  1. Change From Baseline in Measured Glomerular Filtration Rate (mGFR) Using Iohexol Clearance at Week 24

    Measured glomerular filtration rate (mGFR) was determined from iohexol plasma clearance following a single iohexol injection and serial blood sampling. LS mean was estimated using a mixed model for repeated measures (MMRM) including baseline, joint levels of stratification factors, treatment, time, time-by-baseline interaction, and treatment-by-time interaction (Type III sums of squares), with an unstructured covariance matrix. Change from baseline was calculated as the Week 24 Body Surface Area (BSA)-indexed mGFR minus the baseline BSA-indexed mGFR and was reported in milliliters per minute per 1.73 square meters (mL/min/1.73 m²). Only participants with a non-missing baseline value and at least one post-baseline value were analyzed.

    Time frame: Baseline, Week 24

Secondary outcomes

  1. Change From Baseline in Measured Glomerular Filtration Rate (mGFR) Using Iohexol Clearance at Week 16

    Measured glomerular filtration rate (mGFR) was determined from iohexol plasma clearance following a single iohexol injection and serial blood sampling. LS mean was estimated using a mixed model for repeated measures (MMRM) including baseline, joint levels of stratification factors, treatment, time, time-by-baseline interaction, and treatment-by-time interaction (Type III sums of squares), with an unstructured covariance matrix. Change from baseline was calculated as the Week 16 BSA-indexed mGFR minus the baseline BSA-indexed mGFR and was reported in mL/min/1.73 m².

    Time frame: Baseline, Week 16

  2. Percent Change From Baseline in Urine Albumin-to-Creatinine Ratio (UACR) at Week 24

    Urine Albumin-to-Creatinine ratio (UACR) was calculated by the central laboratory from urinary albumin and urinary creatinine measurements. LS mean was estimated using a mixed model for repeated measures (MMRM) including baseline, joint levels of stratification factors, treatment, time, time-by-baseline interaction, and treatment-by-time interaction (Type III sums of squares), with an unstructured covariance matrix. Baseline and postbaseline UACR values were log-transformed for analysis. Model estimates were back-transformed and reported as percent change from baseline. A negative value indicates a decrease from baseline. Only participants with a non-missing baseline value and at least one post-baseline value were analyzed.

    Time frame: Baseline, Week 24

  3. Change From Baseline in Creatinine-Corrected Fractional Urinary Sodium Excretion (FENa) at Week 24

    Creatinine-corrected fractional excretion of sodium (FENa) was calculated as: FENa (%) = 100 × \[(serum creatinine × urine sodium) / (serum sodium × urine creatinine)\]. LS mean was estimated using a mixed model for repeated measures (MMRM) including baseline, joint levels of stratification factors, treatment, time, time-by-baseline interaction, and treatment-by-time interaction (Type III sums of squares), with an unstructured covariance matrix. Change from baseline was calculated as the Week 24 FENa minus the baseline FENa.

    Time frame: Baseline, Week 24

  4. Change From Baseline in Filtration Fraction Estimated From Measured Glomerular Filtration Rate (mGFR) and MRI-Assessed Renal Mean Arterial Flow, Corrected by Hematocrit at Week 24

    Filtration fraction was calculated as non-BSA-indexed mGFR (mL/min) divided by renal plasma flow (mL/min). Renal plasma flow was calculated as MRI-measured renal blood flow × (1 - hematocrit). LS mean was estimated using a mixed model for repeated measures (MMRM) including baseline, joint levels of stratification factors, treatment, time, time-by-baseline interaction, and treatment-by-time interaction (Type III sums of squares), with an unstructured covariance matrix. Change from baseline was calculated as the Week 24 filtration fraction minus the baseline filtration fraction.

    Time frame: Baseline, Week 24

  5. Change From Baseline in Mean Arterial Flow (MAF) at Week 24

    Mean arterial flow (MAF) was the bilateral mean blood flow in the renal arteries measured using phase-contrast magnetic resonance imaging (PC-MRI). LS mean was estimated using a mixed model for repeated measures (MMRM) including baseline, joint levels of stratification factors, treatment, time, time-by-baseline interaction, and treatment-by-time interaction (Type III sums of squares), with an unstructured covariance matrix. Change from baseline was calculated as the Week 24 MAF minus the baseline MAF.

    Time frame: Baseline, Week 24

  6. Change From Baseline in Renal Artery Resistive Index (RARI) at Week 24

    RARI is a dimensionless measure of resistance to renal arterial blood flow and was calculated from phase-contrast magnetic resonance imaging (PC-MRI) as: RARI= (peak systolic velocity \[PSV\]- end-diastolic velocity \[EDV\]) /PSV. RARI has a theoretical range of 0 to 1, with higher values generally representing a less favorable outcome. In general adult population, RARI values of 0.50 to 0.70 are typically considered normal, and values greater than 0.70 are generally considered elevated; however, these reference values are derived from Doppler ultrasound measurements, and MRI-based RARI values may differ and require further validation. LS mean was estimated using a MMRM including baseline, joint levels of stratification factors, treatment, time, time-by-baseline interaction, and treatment-by-time interaction (Type III sums of squares), with an unstructured covariance matrix. Change from baseline was calculated as Week 24 RARI minus the baseline RARI.

    Time frame: Baseline, Week 24

  7. Change From Baseline in Renal Blood Flow Velocity Peak Systolic Velocity (PSV) at Week 24

    Peak systolic velocity (PSV) was the highest renal arterial blood flow velocity measured during systole using cardiac-gated phase-contrast magnetic resonance imaging. LS mean was estimated using a mixed model for repeated measures (MMRM) including baseline, joint levels of stratification factors, treatment, time, time-by-baseline interaction, and treatment-by-time interaction (Type III sums of squares), with an unstructured covariance matrix. Change from baseline was calculated as the Week 24 PSV minus the baseline PSV.

    Time frame: Baseline, Week 24

  8. Change From Baseline in Renal Blood Flow Velocity End-Diastolic Velocity (EDV) at Week 24

    End-diastolic velocity (EDV) was the lowest renal arterial blood flow velocity measured during diastole using cardiac-gated phase-contrast magnetic resonance imaging. LS mean was estimated using a mixed model for repeated measures (MMRM) including baseline, joint levels of stratification factors, treatment, time, time-by-baseline interaction, and treatment-by-time interaction (Type III sums of squares), with an unstructured covariance matrix. Change from baseline was calculated as the Week 24 EDV minus the baseline EDV.

    Time frame: Baseline, Week 24

  9. Percent Change From Baseline in Total Renal Parenchyma Volume (MRI) at Week 24

    Total renal parenchyma volume was measured using magnetic resonance imaging by delineating the corresponding regions of interest on T1 maps. LS mean was estimated using a mixed model for repeated measures (MMRM) including baseline, joint levels of stratification factors, treatment, time, time-by-baseline interaction, and treatment-by-time interaction (Type III sums of squares), with an unstructured covariance matrix. Percent change from baseline in Total Renal Parenchyma Volume was calculated as: 100 × (Week 24 total renal parenchyma volume - baseline total renal parenchyma volume) / baseline total renal parenchyma volume.

    Time frame: Baseline, Week 24

  10. Percent Change From Baseline in Renal Cortex Volume (MRI) at Week 24

    Renal cortex volume was measured using magnetic resonance imaging by delineating the renal cortex region of interest on T1 maps. LS mean was estimated using a mixed model for repeated measures (MMRM) including baseline, joint levels of stratification factors, treatment, time, time-by-baseline interaction, and treatment-by-time interaction (Type III sums of squares), with an unstructured covariance matrix. Percent change from baseline in Renal Cortex Volume was calculated as: 100 × (Week 24 renal cortex volume - baseline renal cortex volume) / baseline renal cortex volume.

    Time frame: Baseline, Week 24

  11. Percent Change From Baseline in Kidney Parenchyma Global Perfusion (MRI) at Week 24

    Kidney parenchyma global perfusion was assessed as the mean renal blood flow per 100 g of kidney tissue measured by magnetic resonance imaging (MRI). LS mean was estimated using a mixed model for repeated measures (MMRM) including baseline, joint levels of stratification factors, treatment, time, time-by-baseline interaction, and treatment-by-time interaction (Type III sums of squares), with an unstructured covariance matrix. Percent change from baseline in Kidney Parenchyma Global Perfusion was calculated as: 100 × (Week 24 kidney parenchyma global perfusion - baseline kidney parenchyma global perfusion) / baseline kidney parenchyma global perfusion.

    Time frame: Baseline, Week 24

  12. Percent Change From Baseline in Renal Cortex T1 (MRI) at Week 24

    Renal cortex T1 was measured using magnetic resonance imaging T1 mapping. LS mean was estimated using a mixed model for repeated measures (MMRM) including baseline, joint levels of stratification factors, treatment, time, time-by-baseline interaction, and treatment-by-time interaction (Type III sums of squares), with an unstructured covariance matrix. Percent change from baseline in Renal Cortex T1 was calculated as: 100 × (Week 24 renal cortex T1 - baseline renal cortex T1) / baseline renal cortex T1.

    Time frame: Baseline, Week 24

  13. Percent Change From Baseline in Renal Medulla T1 (MRI) at Week 24

    Renal medulla T1 was measured using magnetic resonance imaging T1 mapping. LS mean was estimated using a mixed model for repeated measures (MMRM) including baseline, joint levels of stratification factors, treatment, time, time-by-baseline interaction, and treatment-by-time interaction (Type III sums of squares), with an unstructured covariance matrix. Percent change from baseline in Renal Medulla T1 was calculated as: 100 × (Week 24 renal medulla T1 - baseline renal medulla T1) / baseline renal medulla T1.

    Time frame: Baseline, Week 24

  14. Percent Change From Baseline in Renal Cortex R2* at Week 24

    Renal cortex R2\* was measured using blood oxygenation level-dependent magnetic resonance imaging as an indirect assessment of renal oxygenation. LS mean was estimated using a mixed model for repeated measures (MMRM) including baseline, joint levels of stratification factors, treatment, time, time-by-baseline interaction, and treatment-by-time interaction (Type III sums of squares), with an unstructured covariance matrix. Percent change from baseline in Renal Cortex R2\* was calculated as:100 × (Week 24 renal cortex R2\* - baseline renal cortex R2\*) / baseline renal cortex R2\*

    Time frame: Baseline, Week 24

  15. Percent Change From Baseline in Renal Medulla R2* at Week 24

    Renal medulla R2\* was measured using blood oxygenation level-dependent magnetic resonance imaging as an indirect assessment of renal oxygenation. LS mean was estimated using a mixed model for repeated measures (MMRM) including baseline, joint levels of stratification factors, treatment, time, time-by-baseline interaction, and treatment-by-time interaction, with an unstructured covariance matrix. Percent change from baseline in Renal Medulla R2\* was calculated as:100 × (Week 24 renal medulla R2\* - baseline renal medulla R2\*) / baseline renal medulla R2\*.

    Time frame: Baseline, Week 24

  16. Percent Change From Baseline in Body Weight at Week 24

    Body weight was measured in kilograms using a calibrated electronic scale. LS mean was estimated using a mixed model for repeated measures (MMRM) including baseline, joint levels of stratification factors, treatment, time, time-by-baseline interaction, and treatment-by-time interaction (Type III sums of squares), with an unstructured covariance matrix. Percent change from baseline was calculated as: 100 × (Week 24 body weight - baseline body weight) / baseline body weight. A negative value indicates a decrease in body weight.

    Time frame: Baseline, Week 24

  17. Percent Change From Baseline in 24-Hour (hr) Urinary Albumin Excretion (UAE) at Week 24

    Twenty-four-hour urinary albumin excretion (UAE) was derived from the 24-hour urine collection. Percent change from baseline at Week 24 was calculated relative to the baseline UAE value and was reported as %. Values represented under Least Squares (LS) Mean are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using an analysis of covariance (ANCOVA) model for endpoint measures on the log-transformed ratio to baseline, with log-transformed baseline value, treatment, and joint levels of stratification factors included as covariates. LS mean estimates and treatment comparisons were backtransformed and expressed as percent change from baseline. As pre-specified in the Statistical Analysis Plan, missing endpoint values were imputed using primary multiple imputation and combined using Rubin's rules.

    Time frame: Baseline, Week 24

  18. Change From Baseline in 24-Hour (hr) Urinary Electrolytes at Week 24

    Twenty-four-hour urinary electrolyte excretion was derived from the 24-hour urine collection. Change from baseline was calculated as the Week 24 value minus the baseline value. Values represented under Least Squares (LS) Mean are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using an analysis of covariance (ANCOVA) model for endpoint measures, with baseline, treatment, and joint levels of stratification factors included as covariates. As pre-specified in Statistical Analysis Plan, Missing endpoint values were imputed using primary multiple imputation and combined using Rubin's rules.

    Time frame: Baseline, Week 24

08

Results

Posted Nov 9, 2026

Participant flow

Participant flow — Overall Study
MilestonePlaceboRetatrutide
Started7175
Received at least one dose of study drug6973
Completed6058
Not completed1117
Withdrew: Adverse event14
Withdrew: Lost to follow-up11
Withdrew: Non-compliance with study drug01
Withdrew: Physician decision01
Withdrew: Protocol deviation12
Withdrew: Withdrawal by subject66
Withdrew: Iodinated contrast allergy01
Withdrew: Noncompliance with study procedures01
Withdrew: Participant unavailable due to extended travel10
Withdrew: Inability to obtain intravenous (iv) access10

Outcome measures

PrimaryChange From Baseline in Measured Glomerular Filtration Rate (mGFR) Using Iohexol Clearance at Week 24

Measured glomerular filtration rate (mGFR) was determined from iohexol plasma clearance following a single iohexol injection and serial blood sampling. LS mean was estimated using a mixed model for repeated measures (MMRM) including baseline, joint levels of stratification factors, treatment, time, time-by-baseline interaction, and treatment-by-time interaction (Type III sums of squares), with an unstructured covariance matrix. Change from baseline was calculated as the Week 24 Body Surface Area (BSA)-indexed mGFR minus the baseline BSA-indexed mGFR and was reported in milliliters per minute per 1.73 square meters (mL/min/1.73 m²). Only participants with a non-missing baseline value and at least one post-baseline value were analyzed.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · mL/min/1.73 m²
Change From Baseline in Measured Glomerular Filtration Rate (mGFR) Using Iohexol Clearance at Week 24
mL/min/1.73 m²PlaceboRetatrutide
Change From Baseline in Measured Glomerular Filtration Rate (mGFR) Using Iohexol Clearance at Week 24-0.19 ± 2.690-1.62 ± 2.820
Statistical analysis
  • Placebo vs Retatrutide · Mixed Models Analysis · p = 0.714 · Ls mean difference: -1.44 · 95% CI -9.17 to 6.30
SecondaryChange From Baseline in Measured Glomerular Filtration Rate (mGFR) Using Iohexol Clearance at Week 16

Measured glomerular filtration rate (mGFR) was determined from iohexol plasma clearance following a single iohexol injection and serial blood sampling. LS mean was estimated using a mixed model for repeated measures (MMRM) including baseline, joint levels of stratification factors, treatment, time, time-by-baseline interaction, and treatment-by-time interaction (Type III sums of squares), with an unstructured covariance matrix. Change from baseline was calculated as the Week 16 BSA-indexed mGFR minus the baseline BSA-indexed mGFR and was reported in mL/min/1.73 m².

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · mL/min/1.73 m²
Change From Baseline in Measured Glomerular Filtration Rate (mGFR) Using Iohexol Clearance at Week 16
mL/min/1.73 m²PlaceboRetatrutide
Change From Baseline in Measured Glomerular Filtration Rate (mGFR) Using Iohexol Clearance at Week 16-4.08 ± 1.923-4.34 ± 1.993
Statistical analysis
  • Placebo vs Retatrutide · Mixed Models Analysis · p = 0.925 · Ls mean difference: -0.26 · 95% CI -5.76 to 5.24
SecondaryPercent Change From Baseline in Urine Albumin-to-Creatinine Ratio (UACR) at Week 24

Urine Albumin-to-Creatinine ratio (UACR) was calculated by the central laboratory from urinary albumin and urinary creatinine measurements. LS mean was estimated using a mixed model for repeated measures (MMRM) including baseline, joint levels of stratification factors, treatment, time, time-by-baseline interaction, and treatment-by-time interaction (Type III sums of squares), with an unstructured covariance matrix. Baseline and postbaseline UACR values were log-transformed for analysis. Model estimates were back-transformed and reported as percent change from baseline. A negative value indicates a decrease from baseline. Only participants with a non-missing baseline value and at least one post-baseline value were analyzed.

Time frame:
Baseline, Week 24
Reported as:
Geometric least squares mean · Percent change
Percent Change From Baseline in Urine Albumin-to-Creatinine Ratio (UACR) at Week 24
Percent changePlaceboRetatrutide
Percent Change From Baseline in Urine Albumin-to-Creatinine Ratio (UACR) at Week 24-8.75 ± 17.575-53.65 ± 8.267
Statistical analysis
  • Placebo vs Retatrutide · Mixed Models Analysis · p = 0.017 · Ls geometric mean difference: -49.21 · 95% CI -70.59 to -12.28
SecondaryChange From Baseline in Creatinine-Corrected Fractional Urinary Sodium Excretion (FENa) at Week 24

Creatinine-corrected fractional excretion of sodium (FENa) was calculated as: FENa (%) = 100 × \[(serum creatinine × urine sodium) / (serum sodium × urine creatinine)\]. LS mean was estimated using a mixed model for repeated measures (MMRM) including baseline, joint levels of stratification factors, treatment, time, time-by-baseline interaction, and treatment-by-time interaction (Type III sums of squares), with an unstructured covariance matrix. Change from baseline was calculated as the Week 24 FENa minus the baseline FENa.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · Percentage of FENa
Change From Baseline in Creatinine-Corrected Fractional Urinary Sodium Excretion (FENa) at Week 24
Percentage of FENaPlaceboRetatrutide
Change From Baseline in Creatinine-Corrected Fractional Urinary Sodium Excretion (FENa) at Week 240.06 ± 0.075-0.23 ± 0.082
Statistical analysis
  • Placebo vs Retatrutide · Mixed Models Analysis · p = 0.011 · Ls mean difference: -0.29 · 95% CI -0.51 to -0.07
SecondaryChange From Baseline in Filtration Fraction Estimated From Measured Glomerular Filtration Rate (mGFR) and MRI-Assessed Renal Mean Arterial Flow, Corrected by Hematocrit at Week 24

Filtration fraction was calculated as non-BSA-indexed mGFR (mL/min) divided by renal plasma flow (mL/min). Renal plasma flow was calculated as MRI-measured renal blood flow × (1 - hematocrit). LS mean was estimated using a mixed model for repeated measures (MMRM) including baseline, joint levels of stratification factors, treatment, time, time-by-baseline interaction, and treatment-by-time interaction (Type III sums of squares), with an unstructured covariance matrix. Change from baseline was calculated as the Week 24 filtration fraction minus the baseline filtration fraction.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · Unitless
Change From Baseline in Filtration Fraction Estimated From Measured Glomerular Filtration Rate (mGFR) and MRI-Assessed Renal Mean Arterial Flow, Corrected by Hematocrit at Week 24
UnitlessPlaceboRetatrutide
Change From Baseline in Filtration Fraction Estimated From Measured Glomerular Filtration Rate (mGFR) and MRI-Assessed Renal Mean Arterial Flow, Corrected by Hematocrit at Week 24-0.01 ± 0.008-0.02 ± 0.008
Statistical analysis
  • Placebo vs Retatrutide · Mixed Models Analysis · p = 0.187 · Ls mean difference: -0.02 · 95% CI -0.04 to 0.01
SecondaryChange From Baseline in Mean Arterial Flow (MAF) at Week 24

Mean arterial flow (MAF) was the bilateral mean blood flow in the renal arteries measured using phase-contrast magnetic resonance imaging (PC-MRI). LS mean was estimated using a mixed model for repeated measures (MMRM) including baseline, joint levels of stratification factors, treatment, time, time-by-baseline interaction, and treatment-by-time interaction (Type III sums of squares), with an unstructured covariance matrix. Change from baseline was calculated as the Week 24 MAF minus the baseline MAF.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · Milliliter/Minute (mL/min)
Change From Baseline in Mean Arterial Flow (MAF) at Week 24
Milliliter/Minute (mL/min)PlaceboRetatrutide
Change From Baseline in Mean Arterial Flow (MAF) at Week 240.6 ± 22.37-6.9 ± 22.25
Statistical analysis
  • Placebo vs Retatrutide · Mixed Models Analysis · p = 0.812 · Ls mean difference: -7.6 · 95% CI -70.2 to 55.1
SecondaryChange From Baseline in Renal Artery Resistive Index (RARI) at Week 24

RARI is a dimensionless measure of resistance to renal arterial blood flow and was calculated from phase-contrast magnetic resonance imaging (PC-MRI) as: RARI= (peak systolic velocity \[PSV\]- end-diastolic velocity \[EDV\]) /PSV. RARI has a theoretical range of 0 to 1, with higher values generally representing a less favorable outcome. In general adult population, RARI values of 0.50 to 0.70 are typically considered normal, and values greater than 0.70 are generally considered elevated; however, these reference values are derived from Doppler ultrasound measurements, and MRI-based RARI values may differ and require further validation. LS mean was estimated using a MMRM including baseline, joint levels of stratification factors, treatment, time, time-by-baseline interaction, and treatment-by-time interaction (Type III sums of squares), with an unstructured covariance matrix. Change from baseline was calculated as Week 24 RARI minus the baseline RARI.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · Unitless
Change From Baseline in Renal Artery Resistive Index (RARI) at Week 24
UnitlessPlaceboRetatrutide
Change From Baseline in Renal Artery Resistive Index (RARI) at Week 240.02 ± 0.008-0.02 ± 0.008
Statistical analysis
  • Placebo vs Retatrutide · Mixed Models Analysis · p = <.001 · Ls mean difference: -0.04 · 95% CI -0.07 to -0.02
SecondaryChange From Baseline in Renal Blood Flow Velocity Peak Systolic Velocity (PSV) at Week 24

Peak systolic velocity (PSV) was the highest renal arterial blood flow velocity measured during systole using cardiac-gated phase-contrast magnetic resonance imaging. LS mean was estimated using a mixed model for repeated measures (MMRM) including baseline, joint levels of stratification factors, treatment, time, time-by-baseline interaction, and treatment-by-time interaction (Type III sums of squares), with an unstructured covariance matrix. Change from baseline was calculated as the Week 24 PSV minus the baseline PSV.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · centimeters per second (cm/s)
Change From Baseline in Renal Blood Flow Velocity Peak Systolic Velocity (PSV) at Week 24
centimeters per second (cm/s)PlaceboRetatrutide
Change From Baseline in Renal Blood Flow Velocity Peak Systolic Velocity (PSV) at Week 241.12 ± 1.790-2.12 ± 1.762
Statistical analysis
  • Placebo vs Retatrutide · Mixed Models Analysis · p = 0.203 · Ls mean difference: -3.23 · 95% CI -8.24 to 1.77
SecondaryChange From Baseline in Renal Blood Flow Velocity End-Diastolic Velocity (EDV) at Week 24

End-diastolic velocity (EDV) was the lowest renal arterial blood flow velocity measured during diastole using cardiac-gated phase-contrast magnetic resonance imaging. LS mean was estimated using a mixed model for repeated measures (MMRM) including baseline, joint levels of stratification factors, treatment, time, time-by-baseline interaction, and treatment-by-time interaction (Type III sums of squares), with an unstructured covariance matrix. Change from baseline was calculated as the Week 24 EDV minus the baseline EDV.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · cm/s
Change From Baseline in Renal Blood Flow Velocity End-Diastolic Velocity (EDV) at Week 24
cm/sPlaceboRetatrutide
Change From Baseline in Renal Blood Flow Velocity End-Diastolic Velocity (EDV) at Week 24-0.58 ± 0.4420.33 ± 0.436
Statistical analysis
  • Placebo vs Retatrutide · Mixed Models Analysis · p = 0.149 · Ls mean difference: 0.90 · 95% CI -0.33 to 2.14
SecondaryPercent Change From Baseline in Total Renal Parenchyma Volume (MRI) at Week 24

Total renal parenchyma volume was measured using magnetic resonance imaging by delineating the corresponding regions of interest on T1 maps. LS mean was estimated using a mixed model for repeated measures (MMRM) including baseline, joint levels of stratification factors, treatment, time, time-by-baseline interaction, and treatment-by-time interaction (Type III sums of squares), with an unstructured covariance matrix. Percent change from baseline in Total Renal Parenchyma Volume was calculated as: 100 × (Week 24 total renal parenchyma volume - baseline total renal parenchyma volume) / baseline total renal parenchyma volume.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Total Renal Parenchyma Volume (MRI) at Week 24
Percent changePlaceboRetatrutide
Percent Change From Baseline in Total Renal Parenchyma Volume (MRI) at Week 240.19 ± 1.016-5.95 ± 1.053
Statistical analysis
  • Placebo vs Retatrutide · Mixed Models Analysis · p = <.001 · Ls mean difference: -6.14 · 95% CI -9.05 to -3.23
SecondaryPercent Change From Baseline in Renal Cortex Volume (MRI) at Week 24

Renal cortex volume was measured using magnetic resonance imaging by delineating the renal cortex region of interest on T1 maps. LS mean was estimated using a mixed model for repeated measures (MMRM) including baseline, joint levels of stratification factors, treatment, time, time-by-baseline interaction, and treatment-by-time interaction (Type III sums of squares), with an unstructured covariance matrix. Percent change from baseline in Renal Cortex Volume was calculated as: 100 × (Week 24 renal cortex volume - baseline renal cortex volume) / baseline renal cortex volume.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Renal Cortex Volume (MRI) at Week 24
Percent changePlaceboRetatrutide
Percent Change From Baseline in Renal Cortex Volume (MRI) at Week 240.40 ± 1.162-8.38 ± 1.206
Statistical analysis
  • Placebo vs Retatrutide · Mixed Models Analysis · p = <.001 · Ls mean difference: -8.78 · 95% CI -12.11 to -5.46
SecondaryPercent Change From Baseline in Kidney Parenchyma Global Perfusion (MRI) at Week 24

Kidney parenchyma global perfusion was assessed as the mean renal blood flow per 100 g of kidney tissue measured by magnetic resonance imaging (MRI). LS mean was estimated using a mixed model for repeated measures (MMRM) including baseline, joint levels of stratification factors, treatment, time, time-by-baseline interaction, and treatment-by-time interaction (Type III sums of squares), with an unstructured covariance matrix. Percent change from baseline in Kidney Parenchyma Global Perfusion was calculated as: 100 × (Week 24 kidney parenchyma global perfusion - baseline kidney parenchyma global perfusion) / baseline kidney parenchyma global perfusion.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Kidney Parenchyma Global Perfusion (MRI) at Week 24
Percent changePlaceboRetatrutide
Percent Change From Baseline in Kidney Parenchyma Global Perfusion (MRI) at Week 242.58 ± 2.9718.09 ± 3.033
Statistical analysis
  • Placebo vs Retatrutide · Mixed Models Analysis · p = 0.198 · Ls mean difference: 5.50 · 95% CI -2.92 to 13.93
SecondaryPercent Change From Baseline in Renal Cortex T1 (MRI) at Week 24

Renal cortex T1 was measured using magnetic resonance imaging T1 mapping. LS mean was estimated using a mixed model for repeated measures (MMRM) including baseline, joint levels of stratification factors, treatment, time, time-by-baseline interaction, and treatment-by-time interaction (Type III sums of squares), with an unstructured covariance matrix. Percent change from baseline in Renal Cortex T1 was calculated as: 100 × (Week 24 renal cortex T1 - baseline renal cortex T1) / baseline renal cortex T1.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Renal Cortex T1 (MRI) at Week 24
Percent changePlaceboRetatrutide
Percent Change From Baseline in Renal Cortex T1 (MRI) at Week 240.56 ± 0.4812.82 ± 0.494
Statistical analysis
  • Placebo vs Retatrutide · Mixed Models Analysis · p = 0.002 · Ls mean difference: 2.26 · 95% CI 0.88 to 3.63
SecondaryPercent Change From Baseline in Renal Medulla T1 (MRI) at Week 24

Renal medulla T1 was measured using magnetic resonance imaging T1 mapping. LS mean was estimated using a mixed model for repeated measures (MMRM) including baseline, joint levels of stratification factors, treatment, time, time-by-baseline interaction, and treatment-by-time interaction (Type III sums of squares), with an unstructured covariance matrix. Percent change from baseline in Renal Medulla T1 was calculated as: 100 × (Week 24 renal medulla T1 - baseline renal medulla T1) / baseline renal medulla T1.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Renal Medulla T1 (MRI) at Week 24
Percent changePlaceboRetatrutide
Percent Change From Baseline in Renal Medulla T1 (MRI) at Week 24-0.09 ± 0.562-0.05 ± 0.580
Statistical analysis
  • Placebo vs Retatrutide · Mixed Models Analysis · p = 0.965 · Ls mean difference: 0.04 · 95% CI -1.57 to 1.64
SecondaryPercent Change From Baseline in Renal Cortex R2* at Week 24

Renal cortex R2\* was measured using blood oxygenation level-dependent magnetic resonance imaging as an indirect assessment of renal oxygenation. LS mean was estimated using a mixed model for repeated measures (MMRM) including baseline, joint levels of stratification factors, treatment, time, time-by-baseline interaction, and treatment-by-time interaction (Type III sums of squares), with an unstructured covariance matrix. Percent change from baseline in Renal Cortex R2\* was calculated as:100 × (Week 24 renal cortex R2\* - baseline renal cortex R2\*) / baseline renal cortex R2\*

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Renal Cortex R2* at Week 24
Percent changePlaceboRetatrutide
Percent Change From Baseline in Renal Cortex R2* at Week 24-1.94 ± 0.746-1.43 ± 0.764
Statistical analysis
  • Placebo vs Retatrutide · Mixed Models Analysis · p = 0.633 · Ls mean difference: 0.51 · 95% CI -1.61 to 2.63
SecondaryPercent Change From Baseline in Renal Medulla R2* at Week 24

Renal medulla R2\* was measured using blood oxygenation level-dependent magnetic resonance imaging as an indirect assessment of renal oxygenation. LS mean was estimated using a mixed model for repeated measures (MMRM) including baseline, joint levels of stratification factors, treatment, time, time-by-baseline interaction, and treatment-by-time interaction, with an unstructured covariance matrix. Percent change from baseline in Renal Medulla R2\* was calculated as:100 × (Week 24 renal medulla R2\* - baseline renal medulla R2\*) / baseline renal medulla R2\*.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Renal Medulla R2* at Week 24
Percent changePlaceboRetatrutide
Percent Change From Baseline in Renal Medulla R2* at Week 24-1.78 ± 1.324-4.06 ± 1.343
Statistical analysis
  • Placebo vs Retatrutide · Mixed Models Analysis · p = 0.228 · Ls mean difference: -2.29 · 95% CI -6.03 to 1.46
SecondaryPercent Change From Baseline in Body Weight at Week 24

Body weight was measured in kilograms using a calibrated electronic scale. LS mean was estimated using a mixed model for repeated measures (MMRM) including baseline, joint levels of stratification factors, treatment, time, time-by-baseline interaction, and treatment-by-time interaction (Type III sums of squares), with an unstructured covariance matrix. Percent change from baseline was calculated as: 100 × (Week 24 body weight - baseline body weight) / baseline body weight. A negative value indicates a decrease in body weight.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Body Weight at Week 24
Percent changePlaceboRetatrutide
Percent Change From Baseline in Body Weight at Week 24-0.05 ± 0.647-13.83 ± 0.642
Statistical analysis
  • Placebo vs Retatrutide · Mixed Models Analysis · p = <.001 · Ls mean difference: -13.78 · 95% CI -15.59 to -11.98
SecondaryPercent Change From Baseline in 24-Hour (hr) Urinary Albumin Excretion (UAE) at Week 24

Twenty-four-hour urinary albumin excretion (UAE) was derived from the 24-hour urine collection. Percent change from baseline at Week 24 was calculated relative to the baseline UAE value and was reported as %. Values represented under Least Squares (LS) Mean are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using an analysis of covariance (ANCOVA) model for endpoint measures on the log-transformed ratio to baseline, with log-transformed baseline value, treatment, and joint levels of stratification factors included as covariates. LS mean estimates and treatment comparisons were backtransformed and expressed as percent change from baseline. As pre-specified in the Statistical Analysis Plan, missing endpoint values were imputed using primary multiple imputation and combined using Rubin's rules.

Time frame:
Baseline, Week 24
Reported as:
Geometric least squares mean · Percent change
Percent Change From Baseline in 24-Hour (hr) Urinary Albumin Excretion (UAE) at Week 24
Percent changePlaceboRetatrutide
Percent Change From Baseline in 24-Hour (hr) Urinary Albumin Excretion (UAE) at Week 241.5 ± 9.17-36.0 ± 9.22
Statistical analysis
  • Placebo vs Retatrutide · ANCOVA · p = 0.006 · Ls geometric mean difference: -36.9 · 95% CI -54.3 to -12.9
SecondaryChange From Baseline in 24-Hour (hr) Urinary Electrolytes at Week 24

Twenty-four-hour urinary electrolyte excretion was derived from the 24-hour urine collection. Change from baseline was calculated as the Week 24 value minus the baseline value. Values represented under Least Squares (LS) Mean are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using an analysis of covariance (ANCOVA) model for endpoint measures, with baseline, treatment, and joint levels of stratification factors included as covariates. As pre-specified in Statistical Analysis Plan, Missing endpoint values were imputed using primary multiple imputation and combined using Rubin's rules.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · milligrams/24hr (mg/24h)
Change From Baseline in 24-Hour (hr) Urinary Electrolytes at Week 24
milligrams/24hr (mg/24h)PlaceboRetatrutide
Change From Baseline in 24-Hour (hr) Urinary Electrolytes at Week 24116.3 ± 118.36-77.6 ± 22.89
Statistical analysis
  • Placebo vs Retatrutide · ANCOVA · p = 0.103 · Ls mean difference: -193.9 · 95% CI -428.5 to 40.7

Adverse events

Collected over Baseline up to end of follow-up (up to 28 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/69 (0%)6/69 (8.7%)6/69 (8.7%)
Retatrutide0/73 (0%)9/73 (12.3%)17/73 (23.3%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventPlaceboRetatrutide
Prostate cancer stage iiNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/371/42
Acute myocardial infarctionCardiac disorders1/690/73
Atrial fibrillationCardiac disorders1/690/73
Cholecystitis acuteHepatobiliary disorders1/690/73
Skin lacerationInjury, poisoning and procedural complications1/690/73
Colorectal adenomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/690/73
Carotid artery stenosisNervous system disorders1/690/73
Cerebrovascular accidentNervous system disorders1/690/73
Knee arthroplastySurgical and medical procedures1/690/73
HypertensionVascular disorders1/690/73
Most frequent other events
Most frequent other events
EventPlaceboRetatrutide
DiarrhoeaGastrointestinal disorders4/6910/73
NauseaGastrointestinal disorders4/697/73
Decreased appetiteMetabolism and nutrition disorders0/696/73
Gastrooesophageal reflux diseaseGastrointestinal disorders0/694/73
HypotensionVascular disorders3/694/73

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)PlaceboRetatrutideTotal
Mean65.4 ± 10.964.7 ± 10.365.1 ± 10.6
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboRetatrutideTotal
Female343266
Male374380
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboRetatrutideTotal
Hispanic or Latino81119
Not Hispanic or Latino6062122
Unknown or Not Reported325
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboRetatrutideTotal
American Indian or Alaska Native101
Asian8715
Native Hawaiian or Other Pacific Islander000
Black or African American81624
White5250102
More than one race000
Unknown or Not Reported224
Region of Enrollment
Region of Enrollment(Participants)PlaceboRetatrutideTotal
Canada252651
Italy167
Spain8513
United Kingdom6410
United States313465
Measured Glomerular Filtration Rate (mGFR)
Measured Glomerular Filtration Rate (mGFR)(mL/min/1.73 m²)PlaceboRetatrutideTotal
Mean52.91 ± 15.60651.50 ± 15.12952.22 ± 15.323
09

Study locations

42 sites
  • The Institute for Liver Health II dba Arizona Clinical Trials - Mesa
    Chandler, Arizona 85225, United States
  • Care Access - 801 South Power Road, Mesa
    Mesa, Arizona 85206, United States
  • Headlands Research - Scottsdale
    Scottsdale, Arizona 85260, United States
  • Medical Advancement Centers of Arizona
    Tempe, Arizona 85283, United States
  • Hope Clinical Research, Inc.
    Canoga Park, California 91303, United States
  • Catalina Research Institute, LLC
    Montclair, California 91763, United States
  • Peninsula Research Associates
    Rolling Hills Estates, California 90274, United States
  • University of Colorado Anschutz Medical Campus
    Aurora, Colorado 80045, United States
  • Teradan Clinical Trials, LLC
    Brandon, Florida 33511, United States
  • Suncoast Clinical Research, Inc.
    New Port Richey, Florida 34652, United States
  • Great Lakes Clinical Trials - Ravenswood
    Chicago, Illinois 60640, United States
  • Indiana University Health University Hospital
    Indianapolis, Indiana 46202, United States
  • Prime Health and Wellness/SKYCRNG
    Fayette, Mississippi 39069, United States
  • Palm Research Center Tenaya
    Las Vegas, Nevada 89128, United States
  • NYU Langone Hospital - Long Island
    Mineola, New York 11501, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Victorium Clinical Research - Houston
    Houston, Texas 77024, United States
  • Endocrine Ips, Pllc
    Houston, Texas 77079, United States
  • Tranquility Research
    Webster, Texas 77598, United States
  • Centricity Research Brampton Endocrinology
    Brampton, Ontario L6S 0C6, Canada
  • Circulate Cardiac & Vascular Centre
    Burlington, Ontario L7M 1K9, Canada
  • North York Diagnostic and Cardiac Centre
    North York, Ontario M6B 3H7, Canada
  • Stouffville Medical Research Institute Inc.
    Stouffville, Ontario L4A 1H2, Canada
  • Dr. Anil K. Gupta Medicine Professional Corporation
    Toronto, Ontario M9V 4B4, Canada
  • Fadia El Boreky Medicine
    Waterloo, Ontario N2J 1C4, Canada
  • Viacar Recherche Clinique
    Greenfield Park, Quebec J4V 2G8, Canada
  • Diex Recherche Joliette
    Joliette, Quebec J6E 6A9, Canada
  • 9109-0126 Quebec Inc.
    Montreal, Quebec H4N 2W2, Canada
  • Centro Cardiologico Monzino
    Milan, Milano 20138, Italy
  • Azienda Ospedaliera Universitaria Pisana
    Pisa, Tuscany 56126, Italy
  • Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII
    Bergamo, 24127, Italy
  • Ospedale San Raffaele
    Milan, 20132, Italy
  • Hospital Clinico de Valencia
    Valencia, Valenciana, Comunitat 46010, Spain
  • Hospital Universitario Doctor Peset
    Valencia, Valenciana, Comunitat 46017, Spain
  • Clínica nuevas Tecnologías en Diabetes y Endocrinología (NTDE)
    Seville, 41003, Spain
  • Addenbrooke's Hospital
    Cambridge, Cambridgeshire CB2 2QQ, United Kingdom
  • FutureMeds Teesside - Middlefield Centre
    Stockton-on-Tees, Durham County TS19 8PE, United Kingdom
  • Royal London Hospital
    London, England E1 1BB, United Kingdom
  • Futuremeds-Newcastle
    Newcastle, England, United Kingdom
  • Vascular Research Team
    Salford, Greater Manchester M6 8HD, United Kingdom
  • North Middlesex Hospital
    London, London, City of N18 1QX, United Kingdom
  • City Hospital, Nottingham University Hospitals NHS Trust
    Nottingham, NG5 1PB, United Kingdom
10

References and documents

Publications

  • Heerspink HJL, van Raalte DH, Bjornstad P, Bunck MC, Wu P, Tunali I, Milicevic Z, Koeneman L. Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney disease. Nephrol Dial Transplant. 2026 May 29;41(6):1058-1068. doi: 10.1093/ndt/gfaf230. PubMed 41160422 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

11

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2023 to primary completion in Oct 2025, 26 months.

Results were first posted in Nov 2026, 1 year 1 month after primary completion.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 26 months is above that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2023
First posted
Jul 7, 2023
StartActual
Jul 20, 2023
Primary completionActual
Oct 1, 2025
CompletionActual
Oct 21, 2025
Results first posted
Nov 9, 2026
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 9, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedChange fromFrom Baseline in Measured Glomerular Filtration Rate (mGFR) Using Iohexol Clearance at Week 24Time frame: Baseline, Week 24
Nov 9, 2026
Documents
Secondary outcomes
17 edited, 1 added
What changed in the outcomes
  • EditedPercent Change fromFrom Baseline in Urine Albumin-to-Creatinine Ratio (UACR) at Week 24Time frame: Baseline, Week 24
  • EditedChange fromFrom Baseline in Creatinine-Corrected Fractional Urinary Sodium Excretion (FENa) at Week 24Time frame: Baseline, Week 24
  • EditedChange fromFrom Baseline in Filtration Fraction Estimated from Measured Glomerular Filtration Rate (mGFR) Using Iohexol Clearance at Week 16Time frame: Baseline, Week 24 → Baseline, Week 16
  • EditedChange fromFrom Baseline in Renal Mean Arterial Flow as Assessed by Magnetic Resonance Imaging (MRI), Corrected by Hematocrit(MAF) at Week 24Time frame: Baseline, Week 24
  • EditedChange fromFrom Baseline in in Mean ArterialRenal Blood Flow Velocity Peak Systolic Velocity (MAFPSV) at Week 24Time frame: Baseline, Week 24
  • EditedChange fromFrom Baseline in Renal Artery Resistive Index (RARI) at Week 24Time frame: Baseline, Week 24
  • EditedChange fromFrom Baseline in Renal Blood Flow Velocity Peak SystolicEnd-Diastolic Velocity (PSVEDV) and End-diastolic Velocity (ESV)at Week 24Time frame: Baseline, Week 24
  • EditedPercent Change fromFrom Baseline in GlobalTotal Renal PerfusionParenchyma Volume (MRI) at Week 24Time frame: Baseline, Week 24
  • EditedPercent Change fromFrom Baseline in Total Renal ParenchymaCortex Volume (MRI) at Week 24Time frame: Baseline, Week 24
  • EditedPercent Change fromFrom Baseline in Renal Cortex VolumeKidney Parenchyma Global Perfusion (MRI) at Week 24Time frame: Baseline, Week 24
  • EditedPercent Change fromFrom Baseline in Renal Cortex T1 (msMRI) (MRI)at Week 24Time frame: Baseline, Week 24
  • EditedPercent Change fromFrom Baseline in Renal Medulla T1 (msMRI) (MRI)at Week 24Time frame: Baseline, Week 24
  • EditedPercent Change fromFrom Baseline in Renal Cortex R2 (BOLD MRI)* at Week 24Time frame: Baseline, Week 24
  • EditedPercent Change fromFrom Baseline in Renal Medulla R2* at Week 24Time frame: Baseline, Week 24
  • EditedPercent Change fromFrom Baseline in Body Weight at Week 24Time frame: Baseline, Week 24
  • EditedPercent Change fromFrom Baseline in 24-Hour (hr) Urinary Albumin Excretion (UAE) at Week 24Time frame: Baseline, Week 24
  • EditedChange fromFrom Baseline in Change in 24-hourHour (hr) Urinary Electrolytes (milligrams/24hr (mg/24h))at Week 24Time frame: Baseline, Week 24
  • AddedChange From Baseline in Filtration Fraction Estimated From Measured Glomerular Filtration Rate (mGFR) and MRI-Assessed Renal Mean Arterial Flow, Corrected by Hematocrit at Week 24Time frame: Baseline, Week 24
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedChange fromFrom Baseline in Measured Glomerular Filtration Rate (mGFR) Using Iohexol Clearance at Week 24Time frame: Baseline, Week 24
    Secondary outcomes 17 edited, 1 added
    What changed in the outcomes
    • EditedPercent Change fromFrom Baseline in Urine Albumin-to-Creatinine Ratio (UACR) at Week 24Time frame: Baseline, Week 24
    • EditedChange fromFrom Baseline in Creatinine-Corrected Fractional Urinary Sodium Excretion (FENa) at Week 24Time frame: Baseline, Week 24
    • EditedChange fromFrom Baseline in Filtration Fraction Estimated from Measured Glomerular Filtration Rate (mGFR) Using Iohexol Clearance at Week 16Time frame: Baseline, Week 24 → Baseline, Week 16
    • EditedChange fromFrom Baseline in Renal Mean Arterial Flow as Assessed by Magnetic Resonance Imaging (MRI), Corrected by Hematocrit(MAF) at Week 24Time frame: Baseline, Week 24
    • EditedChange fromFrom Baseline in in Mean ArterialRenal Blood Flow Velocity Peak Systolic Velocity (MAFPSV) at Week 24Time frame: Baseline, Week 24
    • EditedChange fromFrom Baseline in Renal Artery Resistive Index (RARI) at Week 24Time frame: Baseline, Week 24
    • EditedChange fromFrom Baseline in Renal Blood Flow Velocity Peak SystolicEnd-Diastolic Velocity (PSVEDV) and End-diastolic Velocity (ESV)at Week 24Time frame: Baseline, Week 24
    • EditedPercent Change fromFrom Baseline in GlobalTotal Renal PerfusionParenchyma Volume (MRI) at Week 24Time frame: Baseline, Week 24
    • EditedPercent Change fromFrom Baseline in Total Renal ParenchymaCortex Volume (MRI) at Week 24Time frame: Baseline, Week 24
    • EditedPercent Change fromFrom Baseline in Renal Cortex VolumeKidney Parenchyma Global Perfusion (MRI) at Week 24Time frame: Baseline, Week 24
    • EditedPercent Change fromFrom Baseline in Renal Cortex T1 (msMRI) (MRI)at Week 24Time frame: Baseline, Week 24
    • EditedPercent Change fromFrom Baseline in Renal Medulla T1 (msMRI) (MRI)at Week 24Time frame: Baseline, Week 24
    • EditedPercent Change fromFrom Baseline in Renal Cortex R2 (BOLD MRI)* at Week 24Time frame: Baseline, Week 24
    • EditedPercent Change fromFrom Baseline in Renal Medulla R2* at Week 24Time frame: Baseline, Week 24
    • EditedPercent Change fromFrom Baseline in Body Weight at Week 24Time frame: Baseline, Week 24
    • EditedPercent Change fromFrom Baseline in 24-Hour (hr) Urinary Albumin Excretion (UAE) at Week 24Time frame: Baseline, Week 24
    • EditedChange fromFrom Baseline in Change in 24-hourHour (hr) Urinary Electrolytes (milligrams/24hr (mg/24h))at Week 24Time frame: Baseline, Week 24
    • AddedChange From Baseline in Filtration Fraction Estimated From Measured Glomerular Filtration Rate (mGFR) and MRI-Assessed Renal Mean Arterial Flow, Corrected by Hematocrit at Week 24Time frame: Baseline, Week 24
    + 5 other changes: index terms, identifiers, verification date, arm descriptions and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

12

Registry details

Key details

Study ID
NCT05936151
Responsible party
Sponsor
First posted
Jul 7, 2023
Start date
Jul 20, 2023
Primary completion
Oct 1, 2025
Completion
Oct 21, 2025
Results posted
Nov 9, 2026
Last update
Nov 9, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Retatrutide

Start the discussion